TVRD Valuation
Tvardi Therapeutics Inc
$
23.600
- Overview
- Forecast
- Valuation
- Earnings
TVRD Relative Valuation
TVRD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TVRD is overvalued; if below, it's undervalued.
Historical Valuation
Tvardi Therapeutics Inc (TVRD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -14.81. The fair price of Tvardi Therapeutics Inc (TVRD) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：23.60
Fair
-13.97
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Tvardi Therapeutics Inc. (TVRD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-9.32
EV/EBIT
Tvardi Therapeutics Inc. (TVRD) has a current EV/EBIT of -9.32. The 5-year average EV/EBIT is -9.71. The thresholds are as follows: Strongly Undervalued below -10.41, Undervalued between -10.41 and -10.06, Fairly Valued between -9.36 and -10.06, Overvalued between -9.36 and -9.00, and Strongly Overvalued above -9.00. The current Forward EV/EBIT of -9.32 falls within the Overvalued range.
0.00
PS
Tvardi Therapeutics Inc. (TVRD) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-7.01
P/OCF
Tvardi Therapeutics Inc. (TVRD) has a current P/OCF of -7.01. The 5-year average P/OCF is -7.43. The thresholds are as follows: Strongly Undervalued below -8.19, Undervalued between -8.19 and -7.81, Fairly Valued between -7.05 and -7.81, Overvalued between -7.05 and -6.67, and Strongly Overvalued above -6.67. The current Forward P/OCF of -7.01 falls within the Overvalued range.
-8.75
P/FCF
Tvardi Therapeutics Inc. (TVRD) has a current P/FCF of -8.75. The 5-year average P/FCF is -9.27. The thresholds are as follows: Strongly Undervalued below -10.22, Undervalued between -10.22 and -9.75, Fairly Valued between -8.80 and -9.75, Overvalued between -8.80 and -8.32, and Strongly Overvalued above -8.32. The current Forward P/FCF of -8.75 falls within the Overvalued range.
Tvardi Therapeutics Inc (TVRD) has a current Price-to-Book (P/B) ratio of -1.48. Compared to its 3-year average P/B ratio of -1.63 , the current P/B ratio is approximately -8.71% higher. Relative to its 5-year average P/B ratio of -1.63, the current P/B ratio is about -8.71% higher. Tvardi Therapeutics Inc (TVRD) has a Forward Free Cash Flow (FCF) yield of approximately -9.76%. Compared to its 3-year average FCF yield of -9.16%, the current FCF yield is approximately 6.59% lower. Relative to its 5-year average FCF yield of -9.16% , the current FCF yield is about 6.59% lower.
-1.53
P/B
Median3y
-1.63
Median5y
-1.63
-9.68
FCF Yield
Median3y
-9.16
Median5y
-9.16
Competitors Valuation Multiple
The average P/S ratio for TVRD's competitors is 22.39, providing a benchmark for relative valuation. Tvardi Therapeutics Inc Corp (TVRD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 20.33%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TVRD increased by 82.10% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.79 to -4.44.
The secondary factor is the Revenue Growth, contributed 20.33%to the performance.
Overall, the performance of TVRD in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
NVDA
NVIDIA Corp
183.160
USD
+0.60%
AMZN
Amazon.com Inc
221.470
USD
+0.08%
TSLA
Tesla Inc
340.840
USD
+0.53%
AAPL
Apple Inc
229.650
USD
+1.09%
META
Meta Platforms Inc
790.000
USD
+3.15%
MSFT
Microsoft Corp
529.240
USD
+1.43%
ORCL
Oracle Corp
253.860
USD
+0.47%
AVGO
Broadcom Inc
312.830
USD
+2.94%
XOM
Exxon Mobil Corp
106.130
USD
+0.28%
WMT
Walmart Inc
103.620
USD
-0.30%
FAQ
Is Tvardi Therapeutics Inc (TVRD) currently overvalued or undervalued?
Tvardi Therapeutics Inc (TVRD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -14.81. The fair price of Tvardi Therapeutics Inc (TVRD) is between to according to relative valuation methord.
What is Tvardi Therapeutics Inc (TVRD) fair value?
How does TVRD's valuation metrics compare to the industry average?
What is the current P/B ratio for Tvardi Therapeutics Inc (TVRD) as of Aug 13 2025?
What is the current FCF Yield for Tvardi Therapeutics Inc (TVRD) as of Aug 13 2025?
What is the current Forward P/E ratio for Tvardi Therapeutics Inc (TVRD) as of Aug 13 2025?